Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Sep;5(9):1655-62.
doi: 10.2215/CJN.09351209. Epub 2010 Jul 1.

Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations

Gil Chernin  1 , Virginia Vega-Warner, Dominik S Schoeb, Saskia F Heeringa, Bugsu Ovunc, Pawaree Saisawat, Roxana Cleper, Fatih Ozaltin, Friedhelm Hildebrandt; Members of the GPN Study Group
Collaborators, Affiliations
Multicenter Study

Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations

Gil Chernin et al. Clin J Am Soc Nephrol. 2010 Sep.

Abstract

Background and objectives: The risk of developing Wilms tumor (WT) can be present or absent in patients with nephrotic syndrome (NS) caused by WT1 mutations. Here, the genotype/phenotype correlation regarding the outcome and risk for WT in 52 patients from 51 families with NS due to WT1 mutations is described.

Design, setting, participants, & measurements: This study followed 19 patients with mutations in intron 9 splice donor site (KTS mutations), 27 patients with missense mutations, 4 patients with nonsense mutations, 1 patient with a splice site mutation in intron 8, and 1 patient with a deletion.

Results: Twenty-four different WT1 mutations were detected. Sixteen of the 19 patients with KTS mutations were females. These patients had isolated NS if karyotype was 46,XX and Frasier syndrome if karyotype was 46,XY. Patients with KTS mutations presented at a significantly older age and with a slower progression toward chronic kidney disease (CKD) stage 5, compared with missense mutations. Patients with nonsense mutations presented initially with WT. Six patients with missense mutations developed WT after the diagnosis of NS (interval-range from NS onset to WT of 0.1 to 1.4 years).

Conclusions: (1) KTS mutations cause isolated NS with absence of WT in 46,XX females. (2) KTS mutations cause Frasier syndrome with gonadoblastoma risk in 46,XY phenotypic females. (3) KTS mutations cause NS with a slower progression when compared with missense mutations. (4) Missense mutations can occur with and without WT. (5) WT1 analysis is important in young patients with NS for early detection and tumor prophylaxis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(Left) NS manifests later in patients with KTS mutations compared with patients with missense mutations in exons 8 or 9 of WT1. Kaplan-Meier survival analysis of interval from birth to onset of NS for 18 patients with splice site mutation in intron 9 (KTS mutations) of WT1 and 27 patients with missense mutations in WT1. The age of NS onset was significantly older in the KTS mutation group compared with patients with missense mutations (t test, P < 0.006). (Right) KTS mutations lead to a slower progression of NS toward CKD stage 5 than missense mutations. Kaplan-Meier survival analysis of interval between onset of NS and CKD stage 5 in 17 patients with splice site mutation in intron 9 (KTS mutations) compared with 26 patients with missense mutations. The vertical latches represent the interval between NS onset and termination of this study for each patient that did not reach CKD stage 5. The interval between onset of NS and CKD stage 5 was significantly longer in the KTS mutation group compared with patients with missense mutations (Log-Rank test, P < 0.006).
Figure 2.
Figure 2.
Tumor risk assessment in patients with nephrotic syndrome and WT1 mutations in exons 8 or 9. GB, gonadoblastoma.
See this image and copyright information in PMC

Comment in

References

    1. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L: Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67: 437–447, 1991 - PubMed
    1. Barbaux S, Niaudet P, Gubler MC, Grünfeld JP, Jaubert F, Kuttenn F, Fékété CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K: Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 17: 467–470, 1997 - PubMed
    1. Ruf RG, Schultheiss M, Lichtenberger A, Karle SM, Zalewski I, Mucha B, Everding AS, Neuhaus T, Patzer L, Plank C, Haas JP, Ozaltin F, Imm A, Fuchshuber A, Bakkaloglu A, Hildebrandt F; APN Study Group: Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 66: 564–570, 2004 - PubMed
    1. Mucha B, Ozaltin F, Hinkes BG, Hasselbacher K, Ruf RG, Schultheiss M, Hangan D, Hoskins BE, Everding AS, Bogdanovic R, Seeman T, Hoppe B, Hildebrandt F; Members of the APN Study Group: Mutations in the Wilms’ tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res 59: 325–331, 2006 - PubMed
    1. Drash A, Sherman F, Hartmann WH, Blizzard RM: A syndrome of pseudohermaphroditism, Wilms’ tumor, hypertension, and degenerative renal disease. J Pediatr 76: 585–593, 1970 - PubMed

Publication types

MeSH terms

Substances